软组织肿瘤讲义资料.pptVIP

成人软组织肉瘤化疗;;;Categories ;The anatomic site of the primary disease;Risk factors;Signs and symptoms;Adult soft tissue sarcoma diagnosed;core needle biopsy;Pathology and staging;;Incidence of Soft Tissue Sarcoma Subtypes (1978-2001);Sites of Metastasis;Contents ;Chemotherapy ;Chemotherapy;Doxorubicin;Doxorubicin;Ifosfamide;Dacarbazine;Temozolamide;Trabectedin (Ecteinascidin-743, ET743, Yondelis) ;Contents ;Treatment;软组织肉瘤: 传统治疗;Surgical Management;Radical Surgical Margin;Amputation;新辅助化疗;新辅助热灌注化疗;辅助化疗;Role of Adjuvant Chemotherapy;Adjuvant Chemotherapy Trials;Meta-Analysis #2;Metastatic diseases chemotherapy;An EORTC STBSG study;Results;Results;Metastaic Soft-Tissue Sarcomas chemotherapy;Metastaic Soft-Tissue Sarcomas chemotherapy;Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline ;Combination Regimens beyond Ifosfamide and Adriamycin ;Fixed-dose rate gemcitabine plus docetaxel as first-line therapyfor metastatic uterine leiomyosarcoma: a Gynecologic OncologyGroup phase II trial;Response ;Fixed-dose rate gemcitabine plus docetaxel as second-linetherapy for metastatic uterine leiomyosarcoma: a GynecologicOncology Group phase II study;CR 6.3% (3/48), PR 20.8% (10/48) ORR 27% (95% confidence interval 15.3%–41.8%). An additional 50% (24/48) SD, clinical benefit rate of 77%. Median PFS for all 48 patients was 6.7+ months (range 0.7 – 27+ months);Adverse events;Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002 ;Investigational New Drugs (targeted therapy);Angiogenesis and STSs;Compassionate use of bevacizumab (Avastin?) in children and young adults with refractory or recurrent solid tumors ;Bevacizumab was administered at 5–10 mg/kg body weight intravenous